Bausch & Lomb Corp 8K

Bausch + Lomb reported strong Q2 2026 results with higher revenue and adjusted EBITDA, narrowed its net loss, raised full-year 2026 guidance, and announced positive pivotal trial results for its enVista Beyond investigational intraocular lens.

On July 29, 2026, Bausch + Lomb Corporation reported its second-quarter 2026 financial results, highlighting broad-based revenue growth to $1.394 billion (up 9% reported and 8% in constant currency versus Q2 2025), segment strength across Vision Care, Surgical and Pharmaceuticals, improved operating performance that turned an $11 million prior-year operating loss into $83 million of operating income, and a reduced GAAP net loss of $14 million alongside higher non-GAAP adjusted EBITDA of $241 million (or $246 million excluding acquired IPR&D). The company also raised its full-year 2026 guidance for revenue to a range of $5.440–$5.540 billion and for adjusted EBITDA excluding acquired IPR&D to $1.025–$1.075 billion, citing continued strong business performance, while providing detail on cash flow improvements, non-GAAP reconciliations, and a pipeline update on positive topline results from a pivotal clinical study of the enVista Beyond investigational intraocular lens, for which it plans further engagement with regulatory authorities. The release additionally noted ongoing separation-related considerations with Bausch Health Companies Inc., detailed risk factors and forward-looking statement caveats, and announced an earnings conference call the same day.

Filing Facts

CIK

1860742

Ticker

-

Form

8K

Source Type

sec

Accession

0001860742-26-000086

Alert Tier

7